

# Douglas Sborov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11101586/publications.pdf>

Version: 2024-02-01

7  
papers

870  
citations

1307594

7  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

911  
citing authors

#	ARTICLE	IF	CITATIONS
1	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
2	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , 2020, 9, 889-911.	2.3	101
3	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. <i>Cancer</i> , 2021, 127, 4198-4212.	4.1	89
4	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021, 35, 189-200.	7.2	56
5	In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. <i>Leukemia</i> , 2020, 34, 317-321.	7.2	34
6	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , 2021, 11, 103.	6.2	32
7	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021, 35, 3526-3533.	7.2	13